Contribution of peptides to multiple sclerosis research

Alcaro, Maria C.; Papini, Anna Maria

doi:10.1002/bip.20498

Cited by 9 publications

(4 citation statements)

References 145 publications

(617 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple sclerosis is considered an autoimmune disease and is characterized by chronic inflammatory demyelination of the central nervous system (CNS), triggered mostly by CD4 + T lymphocytes [1]. Pain is one of the most relevant symptoms of this pathology and has been frequently studied because it affects 50-80% of patients during the progression of the disease [2,3].…”

mentioning

confidence: 99%

Phyllanthus amarus Does Not Affect Hypernociception in Experimental Autoimmune Encephalomyelitis

et al. 2014

View full text Add to dashboard Cite

Multiple sclerosis is an inflammatory disease of the central nervous system. Chronic pain is one of the main symptoms, affecting many patients. Studies show that the lignans or the apolar extracts of Phyllanthus amarus have antinociceptive effects in different animal models. To evaluate the antihypernociceptive effect of a hexanic extract of P. amarus in experimental autoimmune encephalomyelitis in mice, the chemical composition of the hexanic extract was analyzed by gas chromatography mass spectrometry. After EAE induction, animals were treated with the hexanic extract of P. amarus for 26 consecutive days. Motor coordination and mechanical hypernociception were evaluated on alternate days. The principal lignans found were phyllanthin, niranthin, and 5-demethoxyniranthin. The hexanic extract of P. amarus at a dose of 100, 200, or 400 mg/kg did not affect the development of the disease. The motor coordination and pain threshold of the treated animals were not altered in this experiment. In conclusion, in this test, the hexanic extract of P. amarus did not show evidence of antihypernociceptive activity in experimental autoimmune encephalomyelitis.

show abstract

mentioning

confidence: 99%

Phyllanthus amarus Does Not Affect Hypernociception in Experimental Autoimmune Encephalomyelitis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Interestingly Cop-1, which can be considered as an APL in EAE (and possibly MS), is among the first random complex mixture of polypeptides to be used as therapeutic immunomodulator based on the striking property of T cell recognition to harbor a certain degree of degeneracy. Other peptides with similar properties are under investigation [54].…”

Section: Peptides Derived From Autoantigensmentioning

confidence: 98%

Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases

Briand

Muller²

2010

CPD

View full text Add to dashboard Cite

Current pharmacologic treatments for inflammatory diseases are largely palliative rather than curative. Most of them result in nonspecific immunosuppression. This can be associated with disruption of natural and induced immunity with significant, sometimes dramatic, adverse effects. Among the novel strategies that are under development, tools that target specific molecular pathways and cells, and more precisely modulate the immune system to restore normal tolerance mechanisms are central. In these approaches, peptide therapeutics constitute a valuable class of therapeutic agents. They possess a number of intrinsic properties that are favorable for long-term treatments. They are also versatile components that can be modified to improve their capacities without affecting their bioactivity. Peptide-mediated immunotherapy has been evaluated in several appropriate experimental animal models. A few peptides are currently evaluated in clinical trials for the treatment of human chronic inflammatory diseases. In this review we describe a number of these emerging peptide therapeutics. We also discuss future challenges that, in addition to include selection of appropriate peptide drugs, also involve the optimization of peptide dosage and route of administration as well as the improvement of peptide stability for adequate bioavailability and specific targeting.

show abstract

“…Due to MS's disease complexity and heterogeneity, its precise pathology remains unknown and, despite extensive research efforts, specific effective treatments have not yet been developed [27][28][29][30][31]. The recent studies show that there are several pathologic types of MS, including T cell and MQ mediated; in this type demyelination is due to activation of MQs, type 2 is T cell and B cell (antibody) mediated (more common type).…”

Section: Multiple Sclerosismentioning

confidence: 99%

Immunopharmacological role of the Leukotriene Receptor Antagonists and inhibitors of leukotrienes generating enzymes in Multiple Sclerosis

Mirshafiey

Jadidi‐Niaragh

2010

Immunopharmacology and Immunotoxicology

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic inflammatory disease that involves central nervous system, and is generally associated with demyelination and axonal lesion. The effective factors for initiation of the inflammatory responses have not been known precisely so far. Leukotrienes (LTs) are inflammatory mediators with increased levels in the cerebrospinal fluid of MS patients and in experimental models of multiple sclerosis. Inhibition of LT receptors with specific antagonists can decrease inflammatory responses. In this review article we try to clarify the role of LT receptor antagonists and also inhibitors of enzymes which are involved in LTs generating pathway for treating multiple sclerosis as new targets for MS therapy. Moreover, we suggest that blockage of LT receptors by potent specific antagonists and/or agonists can be as a novel useful method in treatment of MS.

show abstract

Contribution of peptides to multiple sclerosis research

Cited by 9 publications

References 145 publications

Phyllanthus amarus Does Not Affect Hypernociception in Experimental Autoimmune Encephalomyelitis

Phyllanthus amarus Does Not Affect Hypernociception in Experimental Autoimmune Encephalomyelitis

Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases

Immunopharmacological role of the Leukotriene Receptor Antagonists and inhibitors of leukotrienes generating enzymes in Multiple Sclerosis

Contact Info

Product

Resources

About